Maxim Group Maintains Bullish Outlook in Athersys (ATHX) Despite Trial Failure and Massive Sell-Off
- Wall St. slips with healthcare, consumer names
- St. Jude Medical (STJ) Mentioned as Short at Muddy Waters
- ITT Educational Services (ESI) Shares Decline on Reports of Increased Oversight
- Mylan's (MYL) Steps on EpiPen Do Not Go Far Enough - Wells Fargo's Maris
- Amazon (AMZN) Announces Car Research Destination Amazon Vehicles
Maxim Group analyst Jason Kolbert reiterated a Buy rating on today's blow-up du jour Athersys (NASDAQ: ATHX) but lowered his price target from $10 to $7 after the company's and partner Pfizer (NYSE: PFE) trial failed to meet its endpoint in Ulcerative Colitis trial.
Kolbert said, "While we are disappointed, we are not totally surprised. This is because we have always felt the trial was aggressive, treating the most difficult patients (who had failed all other therapies) with Multistem. We have for the moment removed the UC indication from our model which lowers our price target to $7, from $10. Remember that this product is partnered with Pfizer so Athersys does not realize the full benefits of the product commercially."
The analyst is not backing away from this positive outlook on Athersys "as we still believe that we can see good data from the stroke trial." He added, "We believe the stroke trial (acute patients) remains the most significant near-term event for Athersys and should not be equated to results in chronic (UC) patients. Enrollment should be complete by this summer, and the stage is set for data this fall."
Shares of Athersys are down 54.4% into the close to $1.25.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: JPMorgan Downgrades Northrop Grumman (NOC) to Neutral
- Jefferies Raises Price Target on Guess? (GES) to $17 Following 2Q Beat
- Jefferies Cuts Price Target on Williams-Sonoma (WSM) to $56 Following 2Q
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Related EntitiesMaxim Group
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!